Your session is about to expire
← Back to Search
Vemurafenib for Thyroid Cancer
Study Summary
This trial will test vemurafenib's ability to target the BRAF gene mutation in people with PTC. Researchers will also look at the drug's safety and side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your blood creatinine level is within a certain range.Your absolute neutrophil count is at least 1.0 x 10^9 per liter.Your hemoglobin level is higher than 9 mg/dL.Your platelet count is at least 100 billion per liter.I am 18 years old or older.I can swallow pills.I can take care of myself and do some daily activities.I have severe nausea, vomiting, or issues absorbing food due to bowel surgery.I have brain metastases that have not been treated.I haven't had chemotherapy or targeted therapy within the last 14 days or 5 half-lives, whichever is longer.I have a heart condition related to long QT syndrome or my heart's electrical activity is abnormal.I do not have serious heart disease or uncontrolled irregular heartbeats.My thyroid cancer is advanced and needs surgery.I am not pregnant or breastfeeding, and if capable of becoming pregnant, I have a recent negative pregnancy test.I have not had surgery for my condition and haven't received MAPK pathway treatments.My thyroid cancer has come back or stayed and needs surgery due to affected lymph nodes.I stopped any antiangiogenic therapy at least 14 days ago and haven't had MAPK targeting therapies.My cancer has the BRAF V600E mutation.My thyroid cancer is mainly papillary and not anaplastic.My liver enzymes are within the required limits.Your bilirubin levels are not too high, unless you have Gilbert's syndrome.You have hepatitis B or C virus infection, unless cleared for treatment by viral hepatitis experts.
- Group 1: Vemurafenib - (Presurgery)
- Group 2: Vemurafenib (Post Surgery) - Group A
- Group 3: Post Surgery - Group B
- Group 4: Vemurafenib - Group C
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any vacancies in this research project for participants?
"According to the latest information on clinicaltrials.gov, this trial is not currently recruiting patients. The study was first posted on 11/7/2012 and updated on 11/3/2021. While this particular research project might be completed, there are many other opportunities for people to get involved in medical trials; as of right now, 289 studies are actively searching for participants."
What are two of the primary conditions that Vemurafenib (Post Surgery) - Group A + C has been shown to be an effective treatment for?
"Vemurafenib (Post Surgery) - Group A + C can be used to treat three different types of cancer: metastatic melanoma, non-small cell lung carcinoma, and unresectable melanoma."
Are patients in danger after taking Vemurafenib (Post Surgery) - Group A + C?
"Vemurafenib (Post Surgery) - Group A + C falls into Phase 2 of clinical trials. This means that while there is data supporting its safety, no efficacy has been proven yet."
Are there other ongoing research studies that use Vemurafenib with post-surgical patients in Groups A and C?
"As of now, there are 49 ongoing trials for Vemurafenib (Post Surgery) - Group A + C. 3 of these studies have reached Phase 3 with the majority being conducted in Toronto, Ontario. Across all 1652 locations worldwide, research is still being done on Vemurafenib (Post Surgery) - Group A + C."
How many individuals are receiving care as part of this research?
"This study is no longer recruiting patients. The listing on clinicaltrials.gov shows that it was posted on November 7th, 2012 and last edited on November 3rd, 2021. For those continuing to look for studies, there are presently 240 trials actively searching for patients with thyroid cancer and 49 Vemurafenib (Post Surgery) - Group A + C studies admitting patients."
Share this study with friends
Copy Link
Messenger